Vertex Pharmaceuticals Inc. MA

VRTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000875320

A

strongest fifth of 370 graded peers in healthcare

rank 59 of 370; percentile 15.7; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	B/C percentile 41.8
Solvency	B percentile 25.5
Growth and financing	C percentile 43.0
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $25.6B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Feb 13, 2026 248 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026
Last close	$499.78 2026-10-16; market equity $126.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis ("CF"), sickle cell disease ("SCD"), transfusion dependent beta thalassemia ("TDT"), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 41.8						
Gross profitability	40.4%	32.3%		32.4	371	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	1.3%	(6.6%)		82.7	812	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	0.8 pts	2.8 pts		10.4	242	2025-12-31
Solvency, sleeve percentile 25.5						
Twelve-month failure probability	0.02%	0.07%		6.9	247	2026-06-30
Altman Z double-prime	7.50	(0.30)		12.8	757	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31						
Current ratio	2.90x	2.96x		56.7	840	2025-12-31
Growth and financing, sleeve percentile 43.0						
Revenue growth, three-year compound	10.4%	10.1%		49.6	414	2025-12-31
Free cash flow growth, three-year compound	(6.6%)	10.9%		81.1	96	2025-12-31
Reinvestment rate	43.2%	37.1%		46.6	104	2025-12-31
Asset growth, three years	12.2%	2.1%		28.6	705	2025-12-31
Net share issuance, one year	(1.1%)	2.5%		9.0	634	2026-02-06

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
54	Janux Therapeutics, Inc. (JANX)	14.4	A	
55	Lantheus Holdings, Inc. (LNTH)	14.6	A	
56	Treace Medical Concepts, Inc. (TMCI)	14.9	A	
57	Harrow, Inc. (HROW)	15.2	A	late filer
58	Edwards Lifesciences Corp. (EW)	15.4	A	
59	Vertex Pharmaceuticals Inc. MA (VRTX)	15.7	A	
60	RxSight, Inc. (RXST)	16.0	A	fortress balance sheet
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Natures Sunshine Products Inc. (NATR)	16.5	A	fortress balance sheet
63	Definium Therapeutics, Inc. (DFTX)	16.8	A	dilution
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	

What the price implies

at the 2026-10-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	39.0%	8.0%	70
Distance from 52-week high	(10.4%)	(33.0%)	80
EBIT to enterprise value	3.5%	(1.7%)	71
Free cash flow yield	2.5%	(1.0%)	68
Book value to price	0.16	0.28	36
Sales to price	0.09	0.31	23
Composite equity issuance, five years	(2.5%)	20.3%	24
Relative strength against the sector, log excess return	0.12	(0.13)	70

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$6.1B
Operating cash flow, four quarters	$4.3B
Months of runway	not finite
Days since last periodic filing	76 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	$550.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$12.0B	2025-12-31	2026-02-13	10-K	26-000056
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.7B	2025-12-31	2026-02-13	10-K	26-000056
3	assets	us-gaap:Assets	$25.6B	2025-12-31	2026-02-13	10-K	26-000056
4	net income	us-gaap:NetIncomeLoss	$4.0B	2025-12-31	2026-02-13	10-K	26-000056
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.6B	2025-12-31	2026-02-13	10-K	26-000056
6	assets	us-gaap:Assets	$22.5B	2024-12-31	2026-02-13	10-K	26-000056
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$11.0B	2024-12-31	2026-02-13	10-K	26-000056
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.5B	2024-12-31	2026-02-13	10-K	26-000056
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.9B	2023-12-31	2026-02-13	10-K	26-000056
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.3B	2023-12-31	2026-02-13	10-K	26-000056
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$8.9B	2022-12-31	2025-02-13	10-K	25-000053
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$1.1B	2022-12-31	2025-02-13	10-K	25-000053
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.6B	2021-12-31	2024-02-15	10-K	24-000062
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$904.2M	2021-12-31	2024-02-15	10-K	24-000062
15	current assets	us-gaap:AssetsCurrent	$11.2B	2025-12-31	2026-02-13	10-K	26-000056
16	current liabilities	us-gaap:LiabilitiesCurrent	$3.9B	2025-12-31	2026-02-13	10-K	26-000056
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$13.6B	2025-12-31	2026-02-13	10-K	26-000056
18	operating income	us-gaap:OperatingIncomeLoss	$4.2B	2025-12-31	2026-02-13	10-K	26-000056
19	book equity	us-gaap:StockholdersEquity	$18.7B	2025-12-31	2026-02-13	10-K	26-000056
20	liabilities	us-gaap:Liabilities	$7.0B	2025-12-31	2026-02-13	10-K	26-000056
21	operating income	us-gaap:OperatingIncomeLoss	$2.9B	2020-12-31	2023-02-10	10-K	23-000007
22	interest expense	us-gaap:InterestExpense	$58.2M	2020-12-31	2021-02-11	10-K	21-000006
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$437.6M	2025-12-31	2026-02-13	10-K	26-000056
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$492.6M	2024-12-31	2026-02-13	10-K	26-000056
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$297.7M	2024-12-31	2026-02-13	10-K	26-000056
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.5B	2023-12-31	2026-02-13	10-K	26-000056
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$200.4M	2023-12-31	2026-02-13	10-K	26-000056
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.1B	2022-12-31	2025-02-13	10-K	25-000053
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$204.7M	2022-12-31	2025-02-13	10-K	25-000053
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$209.8M	2025-12-31	2026-02-13	10-K	26-000056
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$4.6B	2025-12-31	2026-02-13	10-K	26-000056

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	income tax	us-gaap:IncomeTaxExpenseBenefit	$690.0M	2025-12-31	2026-02-13	10-K	26-000056
33	current assets	us-gaap:AssetsCurrent	$9.6B	2024-12-31	2026-02-13	10-K	26-000056
34	current liabilities	us-gaap:LiabilitiesCurrent	$3.6B	2024-12-31	2026-02-13	10-K	26-000056
35	assets	us-gaap:Assets	$22.7B	2023-12-31	2025-02-13	10-K	25-000053
36	assets	us-gaap:Assets	$18.2B	2022-12-31	2024-02-15	10-K	24-000062
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	254,034,190	2026-02-06	2026-02-13	10-K	26-000056
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	256,789,869	2025-02-07	2025-02-13	10-K	25-000053

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.